Eli Lilly’s revenue rises about 48% as strong demand for its GLP-1 therapies lifts sales, according to reports from MarketWatch and Global News (Canada). Both outlets attribute the growth to higher-than-expected consumer and clinical demand for Mounjaro and Zepbound, Lilly’s GLP-1 medicines used to treat Type 2 diabetes and support weight loss. Global News (Canada) reports that Mounjaro sales grow 91% in the second quarter to about US$9.94 billion, exceeding analysts’ expectations. MarketWatch similarly points to demand for Lilly’s GLP-1 drugs as the primary driver of the company’s revenue increase. Together, the articles indicate that Lilly is benefiting from continued market demand for GLP-1 products, with quarterly results coming in above what analysts projected. The reporting also frames these results within broader GLP-1 market competition, noting that Novo Nordisk is another major producer of similar therapies, though the figures cited focus on Lilly’s performance.